Faulty Ryzodeg Insulin Pen Fails to Deliver Insulin

Faulty Ryzodeg Insulin Pen Fails to Deliver Insulin

I contacted Novo Nordisk by phone to request a Ryzodeg insulin pen. Previously, I had been administering my insulin using a syringe and had been keeping my blood sugar levels consistently under control. The insulin pen was delivered to me on March 6, 2026, and I started using it for my morning doses.

On the second morning, after administering my dose, I began feeling weak. According to the readings from my glucose sensor, my blood sugar levels were higher than expected. That evening, I started vomiting, and the following morning, I repeatedly vomited everything I ate. Thinking I might be experiencing a stomach problem, I went directly to the hospital.

When I was admitted to Bodrum Acıbadem Hospital, my blood sugar levels were found to have risen to around 400 mg/dL. I was given insulin intravenously, and my levels gradually returned to normal by the evening. We then tried to regulate my blood sugar again using my own Ryzodeg pen, but my glucose levels increased once more. After several attempts, it became clear that the pen was not delivering any medication into my body at all, meaning that the insulin was not actually being injected. During these attempts, the pen also broke the refill cartridge. As a result of spending three nights trying to determine what was wrong and how to resolve the problem, I had to remain hospitalized.

I consider it extremely serious and irresponsible for a pharmaceutical company to send patients an insulin delivery device without properly checking it beforehand, especially when the medication involved is essential and a malfunction could put someone's life at risk. Furthermore, I discovered that similar complaints had been reported previously, indicating that this may not be an isolated incident affecting only me. I submitted a written complaint to the company's headquarters, but the only response I received was a recommendation to call the customer service hotline. This response was completely inadequate given the seriousness of what I experienced.

I demand that Novo Nordisk ensure that all insulin pens supplied to patients undergo thorough quality and functionality checks before reaching users and fully assume the responsibilities expected of a pharmaceutical company. I also request that a properly functioning, undamaged Ryzodeg insulin pen be provided together with a replacement supply of medication, and that the necessary investigations and preventive measures be implemented to ensure that similar incidents do not happen again.

Comments